Denali Therapeutics Inc. (DNLI)

Denali Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019	2018	2017
Market Capitalization	2,443	2,966	3,777	5,447	10,044	1,673	1,962	1,376
Market Cap Growth	-	-21.48%	-30.66%	-45.77%	500.43%	-14.73%	42.57%	-
Enterprise Value	1,454	1,976	2,494	4,640	8,639	1,326	1,498	970
PE Ratio	-20.42	-20.42	-11.59	-18.74	141.20	-8.46	-54.13	-15.60
PS Ratio	7.39	8.97	34.82	111.93	29.92	62.71	15.19	-
PB Ratio	2.37	2.88	3.62	5.66	8.73	4.24	3.59	2.95
P/FCF Ratio	-8.00	-8.00	-14.39	-24.77	24.32	-9.87	41.99	-17.31
P/OCF Ratio	-8.28	-8.28	-15.43	-25.77	24.14	-11.04	39.15	-17.96
EV/Sales Ratio	4.40	5.98	22.99	95.35	25.74	49.72	11.59	-
EV/EBITDA Ratio	-15.38	-15.38	-7.90	-16.42	107.33	-6.98	-51.95	-11.40
EV/EBIT Ratio	-13.61	-13.61	-7.65	-15.94	120.05	-6.70	-41.32	-11.00
EV/FCF Ratio	-5.33	-5.33	-9.50	-21.10	20.91	-7.83	32.05	-12.20
Debt / Equity Ratio	0.04	0.04	0.05	0.06	0.06	0.17	-	-
Debt / EBITDA Ratio	-0.35	-0.35	-0.17	-0.21	0.80	-0.36	-	-
Debt / FCF Ratio	-0.12	-0.12	-0.20	-0.27	0.16	-0.41	-	-
Quick Ratio	13.27	13.27	3.67	2.29	20.50	9.16	14.16	28.68
Current Ratio	13.65	13.65	3.77	2.37	20.86	9.48	14.67	28.92
Asset Turnover	0.26	0.26	0.08	0.03	0.33	0.04	0.22	0
Return on Equity (ROE)	-13.50%	-13.50%	-35.70%	-28.00%	9.20%	-43.30%	-7.10%	-47.50%
Return on Assets (ROA)	-11.40%	-11.40%	-24.60%	-19.70%	7.10%	-32.00%	-6.10%	-23.30%
Return on Capital (ROIC)	-18.28%	-18.28%	-31.11%	-28.97%	5.10%	-45.97%	-8.48%	-19.35%
Earnings Yield	-5.94%	-4.90%	-8.63%	-5.33%	0.71%	-11.81%	-1.85%	-6.41%
FCF Yield	-15.18%	-12.51%	-6.95%	-4.04%	4.11%	-10.13%	2.38%	-5.78%
Buyback Yield / Dilution	-9.43%	-9.43%	-3.30%	-1.34%	-25.43%	-3.22%	-518.96%	-132.92%
Total Shareholder Return	-9.43%	-9.43%	-3.30%	-1.34%	-25.43%	-3.22%	-518.96%	-132.92%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).